Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
DFV-890 by Novartis for Inflammation: Likelihood of Approval
DFV-890 is under clinical development by Novartis and currently in Phase II for Inflammation. According to GlobalData, Phase II drugs...
Data Insights
DFV-890 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
DFV-890 is under clinical development by Novartis and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease)....